Matches in Ubergraph for { <http://purl.obolibrary.org/obo/NCIT_C121625> ?p ?o ?g. }
Showing items 1 to 55 of
55
with 100 items per page.
- NCIT_C121625 IAO_0000115 "A humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1), with immune checkpoint inhibitory and antineoplastic activities. Upon administration, spartalizumab binds to PD-1 expressed on activated T-cells and blocks the interaction with its ligands, programmed cell death 1 ligand 1 (PD-L1, PD-1L1) and PD-1 ligand 2 (PD-L2, PD-1L2). The inhibition of ligand binding prevents PD-1-mediated signaling and results in both T-cell activation and the induction of T-cell-mediated immune responses against tumor cells. PD-1, an immunoglobulin (Ig) superfamily transmembrane protein and inhibitory receptor, negatively regulates T-cell activation." @default.
- NCIT_C121625 NCIT_A32 NCIT_C1909 @default.
- NCIT_C121625 NCIT_A7 NCIT_C94697 @default.
- NCIT_C121625 NCIT_NHC0 "C121625" @default.
- NCIT_C121625 NCIT_P106 "Amino Acid, Peptide, or Protein" @default.
- NCIT_C121625 NCIT_P106 "Immunologic Factor" @default.
- NCIT_C121625 NCIT_P106 "Pharmacologic Substance" @default.
- NCIT_C121625 NCIT_P107 "Spartalizumab" @default.
- NCIT_C121625 NCIT_P108 "Spartalizumab" @default.
- NCIT_C121625 NCIT_P208 "CL507832" @default.
- NCIT_C121625 NCIT_P210 "1935694-88-4" @default.
- NCIT_C121625 NCIT_P319 "QOG25L6Z8Z" @default.
- NCIT_C121625 NCIT_P322 "CTRP" @default.
- NCIT_C121625 NCIT_P322 "FDA" @default.
- NCIT_C121625 NCIT_P322 "GDC" @default.
- NCIT_C121625 NCIT_P329 "770801" @default.
- NCIT_C121625 NCIT_P330 "770801" @default.
- NCIT_C121625 NCIT_P375 "Spartalizumab" @default.
- NCIT_C121625 NCIT_P399 "770801" @default.
- NCIT_C121625 NCIT_R124 NCIT_C17710 @default.
- NCIT_C121625 NCIT_R124 NCIT_C17828 @default.
- NCIT_C121625 NCIT_R124 NCIT_C18219 @default.
- NCIT_C121625 NCIT_R124 NCIT_C19986 @default.
- NCIT_C121625 NCIT_R124 NCIT_C40474 @default.
- NCIT_C121625 normalizedInformationContent "100" @default.
- NCIT_C121625 referenceCount "1" @default.
- NCIT_C121625 hasExactSynonym "PDR-001" @default.
- NCIT_C121625 hasExactSynonym "PDR001" @default.
- NCIT_C121625 hasExactSynonym "SPARTALIZUMAB" @default.
- NCIT_C121625 hasExactSynonym "Spartalizumab" @default.
- NCIT_C121625 inSubset NCIT_C116977 @default.
- NCIT_C121625 inSubset NCIT_C116978 @default.
- NCIT_C121625 inSubset NCIT_C128784 @default.
- NCIT_C121625 inSubset NCIT_C157711 @default.
- NCIT_C121625 inSubset NCIT_C157712 @default.
- NCIT_C121625 inSubset NCIT_C176424 @default.
- NCIT_C121625 inSubset NCIT_C177537 @default.
- NCIT_C121625 inSubset NCIT_C63923 @default.
- NCIT_C121625 type Class @default.
- NCIT_C121625 isDefinedBy ncit.owl @default.
- NCIT_C121625 label "Spartalizumab" @default.
- NCIT_C121625 subClassOf NCIT_C121625 @default.
- NCIT_C121625 subClassOf NCIT_C124946 @default.
- NCIT_C121625 subClassOf NCIT_C128037 @default.
- NCIT_C121625 subClassOf NCIT_C129821 @default.
- NCIT_C121625 subClassOf NCIT_C129822 @default.
- NCIT_C121625 subClassOf NCIT_C141144 @default.
- NCIT_C121625 subClassOf NCIT_C143250 @default.
- NCIT_C121625 subClassOf NCIT_C163758 @default.
- NCIT_C121625 subClassOf NCIT_C1908 @default.
- NCIT_C121625 subClassOf NCIT_C1909 @default.
- NCIT_C121625 subClassOf NCIT_C20401 @default.
- NCIT_C121625 subClassOf NCIT_C274 @default.
- NCIT_C121625 subClassOf NCIT_C307 @default.
- NCIT_C121625 subClassOf NCIT_C308 @default.